US FDA says Bayesian analysis could cut device trial costs

By Staff Reporter

- Last updated on GMT

Related tags: Scientific method

The US Food and Drug Administration (FDA) has issued guidance on the use of Bayesian analysis in clinical trials of medical devices and says the technique can cut costs and boost efficiency.

Commonly used frequency-based statistical methods only allow data from previous studies to be factored into new trials at the design stage, rather than the analysis stage where information is considered an adjunct to, not part of, new results.

In contrast, the Bayesian approach being advocated by the FDA view data from both old and new studies as a continuous stream of information, enabling available information to be considered during results analysis.

The FDA believes that: “When good prior information on clinical use of a device exists, the Bayesian approach may enable this information to be incorporated into the statistical analysis of a trial. In some circumstances, the prior information for a device may be a justification for a smaller-sized or shorter-duration pivotal trial​.”

According to the agency Bayesian analysis is particularly suited to medical devices because, unlike pharmaceuticals, their effects are usually physical and therefore limited to specific areas rather than systemic.

It added that: “As a result, device effects are typically local, not systemic. Local effects can sometimes be predictable from prior information on the previous generations of a device when modifications to the device are minor.

The FDA went on to says that Bayesian methods can also be used to include information from medical device trials conducted overseas, which would be more problematic with drugs.

In a statement accompanying the launch, FDA commissioner Margaret Hamburg said the new guidelines are consistent with the agency’s “commitment to streamline clinical trials, when possible, in order to get safe and effective products to the market faster​.”

While the FDA's support for Bayesian analysis is patient focused, the new guidance focus on cost reduction means will surely be welcomed by medical device developers and the increasing number of contract research organisations (CROs) offering biostatistics services.

The guidance document can be found here​.

Related news

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars